PHILADELPHIA–(BUSINESS WIRE)–Chimeron Bio, a leading RNA company pioneering a novel class of mRNA-based vaccines and therapeutics is pleased to announce the appointment of Dr. Antonin (Tony) de Fougerolles, CEO of Evox Therapeutics to its Scientific Advisory Board.
“The last few months have demonstrated the power of mRNA drug modalities. At Chimeron Bio, we are advancing a novel mRNA approach, and having Tony, a leader in this space, will help build a robust pipeline of RNA vaccines and therapeutics necessary to propel the company to the next level”
A distinguished RNA biologist, Dr. de Fougerolles has a strong track record of advancing new drug modalities to the market and building several multi-billion-dollar companies including Ablynx (a Sanofi Company), Alnylam and Moderna. Tony joining Chimeron Bio is timely as the company leverages the superior properties of its proprietary RNA platform technology including low dose formulation, scalable manufacturing and 4 degree centigrade stability to advance its highly differentiated COVID-19 vaccine to the clinic as well as establish a pipeline in other vaccines and therapeutics.
“The last few months have demonstrated the power of mRNA drug modalities. At Chimeron Bio, we are advancing a novel mRNA approach, and having Tony, a leader in this space, will help build a robust pipeline of RNA vaccines and therapeutics necessary to propel the company to the next level,” said Dr. Afshin Safavi, Chairman of the Board.
“Chimeron Bio is poised to grow and expand its presence in oncology and infectious diseases. Tony’s experience in moving RNA drugs to the market and establishing strong companies is a huge addition to Chimeron,” said Dr. Jolly Mazumdar, Founder and CEO.
“I am pleased to join the Chimeron Bio Scientific Advisory Board and help advance the self-amplifying RNA ChaESARTM platform, which I believe represents the next generation of mRNA drugs,” said Dr. de Fougerolles.
About Chimeron Bio
Chimeron Bio is a biotechnology company focused on the research of self-amplifying RNA (saRNA) towards development of novel RNA drugs and vaccines for various diseases. The company is using its proprietary ChaESARTM platform to develop a pipeline in oncology, rare genetic disorders, and infectious diseases. It is developing two COVID-19 vaccine candidates each with its unique mechanism of action. The candidates have shown strong promise in preclinical studies and are under safety assessment. For more information, visit www.chimeron.com.
Jolly Mazumdar, Ph.D.